Although the enzyme lecithin cholesterol ester transfer protein (LCAT) has been proposed as a unique tool to evaluate the impact of alterations in the HDL system on the progression of renal disease, LysoPCs concentration also depends on LCAT, which activity is decreased in CKD patients [27]. The gene discussed is LCAT; the disease is kidney disorder.